RFP, CGN and CGA Opportunities

The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at

American Academy of Dermatology

The Academy bestows a number of prestigious awards to recognize the contributions of individuals to the specialty as well as offering various grants and scholarships to assist recipients in furthering their areas of study and broadening knowledge in the field of dermatology.

Program for Innovative Continuing Medical Education in Dermatology (PICMED)

The program was established to facilitate dermatologists' continuing education through support and development of innovative continuing medical education programs.

Available grants

  • Multi-year grant: Applicants may request up to $50,000 (direct costs only) for a two (2) year funding period.  2nd year funding will be contingent on 1st year milestones being met. 
  • Single-year grant: Applicants may request up to $10,000 (direct costs only) for a one (1) year project period. 

For more information regarding PICMED, please visit the AAD website.


Bioverativ Therapeutics is committed to supporting innovative, high quality, independent medical education for healthcare professionals (HCPs) that narrows unmet educational needs, maintains clinical excellence, and is designed to change HCP competence and performance, ultimately leading to improved outcomes in the patient communities that Bioverativ serves.

The intent of the Request for Educational Grant Applications (REGA) announcement is to notify experienced and eligible medical education providers that Bioverativ is interested in receiving applications for independent medical education activities pertinent to hemophilia or other rare blood disorders and are related to these therapeutic areas:

  • Inhibitor Management in Hemophilia
  • Patient Management in Cold Agglutinin Disease
  • Factor vs. Non-Factor in Hemophilia
  • Joint Health in Hemophilia

To access these Request for Grant Applications, please visit the Bioverativ Grants and Giving website

Bristol-Myers Squibb

Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.

  • Cardiovascular
  • Immunoscience
  • Oncology
  • Virology
  • Genetically Defined / Rare Diseases

View Request for Proposals / for Education

Insmed Incorporated

Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at Grant submissions should align to the specifications in the downloadable CGA.

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Local and Regional Education Activities

Submission Deadline: Rolling submissions accepted for 2017/2018
Download Call for Grants

Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Education Activities associated with Medical Society Conferences

Submission Deadline: at least 60 days prior to the requestors need for funding commitment, or based on society deadlines.
Download Call for Grants

Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)

The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities. 

On March 2, 2018 CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP). 

For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on

Pfizer Independent Grants for Learning & Change (IGLC)

The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States. 

In order to reduce the development and spread of resistant bacteria and deliver better patient outcomes, healthcare organizations must implement measures to ensure optimal use of antibiotics. Implementation of an antimicrobial stewardship program will help organizations reach the goal of providing patients requiring antibiotic treatment with the right antibiotic(s), at the right time, at the right dose, and for the right duration. We are seeking quality improvement research, health services research and/or educational research applications that identify and evaluate practices for successfully implementing key elements of antimicrobial stewardship programs within hospitals and other healthcare organizations.

Refer to complete details in the RFP document. Questions regarding this RFP should be directed to Pfizer Grant Officer Angelo Carter (